Did you know? You can suggest edits to improve this peptide information.
Overview
What is Thymosin Alpha 1?
Thymosin Alpha 1 (Ta1/Thymalfasin/Zadaxin) is a synthetic 28-amino acid peptide identical to the naturally occurring thymic hormone. With over 11,000 patients studied across 30+ clinical trials, it holds FDA orphan drug designations for four conditions and is approved in 35+ countries worldwide. Ta1 demonstrates exceptional safety with less than 1% serious adverse events while providing comprehensive immune system modulation.
Key Benefits
Primary FDA-studied route with extensive clinical data. Maximum immune modulation through systemic circulation. Established dosing protocols from 35+ countries of clinical use.
Mechanism of Action
Injectable Ta1 provides optimal bioavailability (90-95%) with rapid Tmax of 2 hours. Activates multiple TLR pathways, enhances T-cell maturation, stimulates NK cells, and modulates dendritic cell function through systemic circulation.
Molecular Information
Weight
3,108 Da
Length
28 amino acids
Type
Acetylated polypeptide
Amino Acid Sequence:
Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH
* N-terminal acetylated synthetic peptide identical to naturally occurring thymic hormone
Pharmacokinetics
Research Indications
Primary Immunodeficiencies
FDA orphan drug designation for DiGeorge syndrome with documented restoration of T-cell function and immune competence in clinical trials.
Vaccine Response Enhancement
Enhances immunogenicity in elderly and hemodialysis patients with improved antibody responses to H1N1 and COVID-19 vaccines.
HIV/AIDS Immune Support
Restores CD4+ T-cell counts and reduces opportunistic infections in HIV patients with sustained immunological improvement.
Research Protocols
Disclaimer
These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.
Timing
Injectable Ta1 can be administered at any time. Maintain consistent twice-weekly schedule (e.g., Monday/Thursday or Tuesday/Friday). Rotate injection sites to prevent tissue irritation.
Peptide Interactions
How to Reconstitute
Important
Always use bacteriostatic water (BAC). Sterile technique is essential.
Clean work area and hands thoroughly
Add 1.0 mL sterile water slowly to lyophilized powder
Inject water slowly down vial side (not directly onto powder)
Gently swirl until completely dissolved (never shake)
Final concentration: 1.6 mg/mL
Use promptly or refrigerate at 2-8°C for up to 7 days
Quality Indicators
White Lyophilized Powder
Properly freeze-dried Ta1 appears as white, fluffy powder that fills most of vial bottom. Professional pharmaceutical packaging.
Clear Solution After Reconstitution
When mixed with sterile water, solution should be crystal clear with no particles, cloudiness, or precipitation.
Proper Pharmaceutical Labeling
Vials should have clear labeling with batch numbers, expiration dates, and 1.6mg dosage clearly marked.
Minor Powder Compaction
Slight compaction during shipping is acceptable if powder dissolves completely with gentle mixing.
Discolored or Collapsed Powder
Yellow, brown, or collapsed powder indicates degradation from heat exposure or moisture damage.
Persistent Cloudiness
Solution remains cloudy, contains particles, or shows precipitation after reconstitution - indicates degraded product.
What to Expect
- Week 1-2: Initial immune system activation
- Week 2-6: Enhanced immune function and reduced infection risk
- Week 6-12: Maximum immunomodulatory benefits
- Week 12+: Sustained immune support with continued use
- Most effective for: Immune deficiencies, chronic infections, vaccine enhancement
Side Effects & Safety
- Exceptional safety profile with <1% serious adverse events across 11,000+ patients
- Most common side effect: mild injection site reactions (<10%)
- Contraindicated in organ transplant recipients (risk of graft rejection)
- Monitor for hypersensitivity reactions with first dose
- Not recommended during pregnancy or breastfeeding
References
Comprehensive Safety Evaluation Study (2024)
Comprehensive review across 11,000+ patients in 30+ clinical trials showing <1% serious adverse events, establishing excellent long-term safety profile for potential clinical applications.
View Study (opens in new tab) →Post-Acute COVID-19 Immune Restoration Study
Study demonstrating Ta1's ability to restore immune homeostasis in lymphocytes during post-acute sequelae of SARS-CoV-2 infection with normalized T-cell populations and reduced inflammatory markers.
View Study (opens in new tab) →Cytokine Storm Mitigation in COVID-19 Patients
Clinical study showing significant reduction in pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 while maintaining balanced immune responses in coronavirus disease patients.
View Study (opens in new tab) →Quick Start Guide
Community Poll
Question 1 of 10
What is your experience with this compound?
Poll Results
Loading results...
Community Insights
Self-reported by PepPedia users. Not clinical evidence. Health changes reflect all users, including those taking multiple compounds.
Was this helpful?
Your feedback helps us improve PepPedia